Martin Wermke

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr et al. · Blood · 2002 · 1.7K citations · Full text

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke et al. · Leukemia · 2011 · 391 citations · Full text

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 344 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Immunotherapy +17

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster et al. · Blood · 2020 · 307 citations · Full text

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 271 citations · Full text

Urothelial Carcinomas, Medicine, Clinical Trials +9